Effect of corticosteroid therapy in the early phase of acute respiratory distress syndrome: a propensitymatched cohort study
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: It is unclear whether corticosteroid use in patients with acute respiratory distress syndrome (ARDS) improves survival. This study aimed to investigate whether the administration of corticosteroids to patients in the early phase of moderate to severe ARDS is associated with improved outcomes. Methods: We analyzed the data of patients who received corticosteroids within 7 days of the onset of ARDS between June 2006 and December 2015 at a single tertiary teaching hospital. A total of 565 patients admitted with moderate to severe ARDS were eligible. The outcomes of patients treated with methylprednisolone 40 to 180 mg/day or equivalent (n = 404) were compared to those who did not receive steroids (n = 161). The primary and secondary outcomes were 28- and 90-day mortality rates, respectively. Propensity scores were used to adjust for baseline covariates. Results: The overall mortality at 28 days was not significantly different between the corticosteroid-treated and control groups (43.8% vs. 41%, p = 0.541). At 90 days, the overall mortality rate was higher in the corticosteroid-treated group than in the control group (59.2% vs. 48.4%, p = 0.021). However, on propensity score matching, corticosteroid therapy was not associated with a higher 28-day mortality rate (odds ratio, 1.031; 95% confidence interval, 0.657 to 1.618; p = 0.895) and 90 days (odds ratio, 1.435; 95% confidence interval, 0.877 to 2.348; p = 0.151). Conclusions: Corticosteroid therapy was not associated with 28- or 90-day mortality in the
Abstract
Background/Aims: It is unclear whether corticosteroid use in patients with acute respiratory distress syndrome (ARDS) improves survival. This study aimed to investigate whether the administration of corticosteroids to patients in the early phase of moderate to severe ARDS is associated with improved outcomes. Methods: We analyzed the data of patients who received corticosteroids within 7 days of the onset of ARDS between June 2006 and December 2015 at a single tertiary teaching hospital. A total of 565 patients admitted with moderate to severe ARDS were eligible. The outcomes of patients treated with methylprednisolone 40 to 180 mg/day or equivalent (n = 404) were compared to those who did not receive steroids (n = 161). The primary and secondary outcomes were 28- and 90-day mortality rates, respectively. Propensity scores were used to adjust for baseline covariates. Results: The overall mortality at 28 days was not significantly different between the corticosteroid-treated and control groups (43.8% vs. 41%, p = 0.541). At 90 days, the overall mortality rate was higher in the corticosteroid-treated group than in the control group (59.2% vs. 48.4%, p = 0.021). However, on propensity score matching, corticosteroid therapy was not associated with a higher 28-day mortality rate (odds ratio, 1.031; 95% confidence interval, 0.657 to 1.618; p = 0.895) and 90 days (odds ratio, 1.435; 95% confidence interval, 0.877 to 2.348; p = 0.151). Conclusions: Corticosteroid therapy was not associated with 28- or 90-day mortality in the
참고문헌 (29)
- Koh Y, "Update in acute respiratory distress syndrome", J Intensive Care, 2, pp.2~ (2014)
- Matthay MA, "The acute respiratory distress syndrome", J Clin Invest, 122, pp.2731~2740 (2012)
- Piantadosi CA, "The acute respiratory distress syndrome", Ann Intern Med, 141, pp.460~470 (2004)
- Bernard GR, "The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination", Am J Respir Crit Care Med, 149(3 Pt 1), pp.818~824 (1994)
- Bernard GR, "High-dose corticosteroids in patients with the adult respiratory distress syndrome", N Engl J Med, 317, pp.1565~1570 (1987)
- Steinberg KP, "Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome", N Engl J Med, 354, pp.1671~1684 (2006)
- Meduri GU, "Methylprednisolone infusion in early severe ARDS : results of a randomized controlled trial", Chest, 131, pp.954~963 (2007)
- Meduri GU, "Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome : a randomized controlled trial", JAMA, 280, pp.159~165 (1998)
- Yang ZG, "Early application of low-dose glucocorticoid improves acute respiratory distress syndrome : a meta-analysis of randomized controlled trials", Exp Ther Med, 13, pp.1215~1224 (2017)
- Tang BM, "Use of corticosteroids in acute lung injury and acute respiratory distress syndrome : a systematic review and meta-analysis", Crit Care Med, 37, pp.1594~1603 (2009)
- Takaki M, "The negative effect of initial high-dose methylprednisolone and tapering regimen for acute respiratory distress syndrome : a retrospective propensity matched cohort study", Crit Care, 21, pp.135~ (2017)
- Kido T, "The relationship between high-dose corticosteroid treatment and mortality in acute respiratory distress syndrome : a retrospective and observational study using a nationwide administrative database in Japan", BMC Pulm Med, 18, pp.28~ (2018)
- ARDS Definition Task Force, "Acute respiratory distress syndrome : the Berlin Definition", JAMA, 307, pp.2526~2533 (2012)
- Kalil AC, "Management of adults with hospital-acquired and ventilator-associated pneumonia : 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society", Clin Infect Dis, 63, pp.e61~e111 (2016)
- American Thoracic Society, "Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia", Am J Respir Crit Care Med, 171, pp.388~416 (2005)
- Singer M, "The third international consensus definitions for sepsis and septic shock(sepsis-3)", JAMA, 315, pp.801~810 (2016)
- Lee HS, "Low-dose steroid therapy at an early phase of postoperative acute respiratory distress syndrome", Ann Thorac Surg, 79, pp.405~410 (2005)
- Meduri GU, "Prolonged glucocorticoid treatment is associated with improved ARDS outcomes : analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature", Intensive Care Med, 42, pp.829~840 (2016)
- Agarwal R, "Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis", Respirology, 12, pp.585~590 (2007)
- Thille AW, "Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage : a prospective cohort study of clinical autopsies", Lancet Respir Med, 1, pp.395~401 (2013)
- Peter JV, "Corticosteroids in the prevention and treatment of acute respiratory distress syndrome(ARDS)in adults : meta-analysis", BMJ, 336, pp.1006~1009 (2008)
- Ruan SY, "Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome : a systematic review and meta-analysis", Crit Care, 18, pp.R63~ (2014)
- Cullen DJ, "The incidence of ventilator-induced pulmonary barotrauma in critically ill patients", Anesthesiology, 50, pp.185~190 (1979)
- De Lassence A, "Pneumothorax in the intensive care unit : incidence, risk factors, and outcome", Anesthesiology, 104, pp.5~13 (2006)
- 조영재, "Clinical Practice Guideline of Acute Respiratory Distress Syndrome", Tuberculosis and Respiratory Diseases, 79(4), pp.214~233 (2016), 대한결핵및호흡기학회
- Claesson J, "Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome", Acta Anaesthesiol Scand, 60, pp.697~709 (2016)
- Annane D, "Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency(CIRCI)in critically ill patients(part I) : Society of Critical Care Medicine(SCCM)and European Society of Intensive Care Medicine(ESICM)2017", Intensive Care Med, 43, pp.1751~1763 (2017)
- Hashimoto S, "The clinical practice guideline for the management of ARDS in Japan", J Intensive Care, 5, pp.50~ (2017)
- Rhodes A, "Surviving sepsis campaign : international guidelines for management of sepsis and septic shock : 2016", Intensive Care Med, 43, pp.304~377 (2017)